Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Forecast With Insights On Demand And Industry Growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Over The 2026–2030 Period?
The adeno-associated virus (avv) vectors in gene therapy market has experienced substantial expansion in recent years. This market is projected to grow from $3.16 billion in 2025 to $3.7 billion in 2026, registering a compound annual growth rate (CAGR) of 17.3%. Historically, this growth can be attributed to advances in viral vector safety, increased research into rare genetic disorders, successful clinical gene therapy outcomes, a rise in regulatory approvals, and considerable investments in academic research.
The adeno-associated virus (avv) vectors in gene therapy market is projected for substantial expansion over the coming years, expected to attain a valuation of $6.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.2%. This projected increase can be attributed to factors such as the introduction of commercial gene therapies, the demand for scalable vector production, the growth of precision medicine, incentives for orphan drugs, and an uptick in global clinical trials. Notable developments anticipated during this timeframe encompass the proliferation of gene augmentation therapies, a rising need for gene treatments for rare diseases, advancements in in vivo gene delivery, augmented commercial-scale vector manufacturing, and a concentrated effort on ensuring long-term therapeutic durability.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp
Which Primary Drivers Are Impacting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?
The escalating emphasis on gene-based therapies is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving forward. Gene-based therapies are treatments designed to modify or manipulate genes for the prevention, treatment, or cure of diseases at a molecular level. Progress in genetic research underpins this growing focus on developing gene-based therapies, as it enhances the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy facilitate the creation of gene-based therapies by safely and efficiently delivering therapeutic genes into target cells, due to their low immunogenicity and capacity for long-term gene expression. Illustratively, in 2023, global spending on cell and gene therapies reached $5.9 billion, a 38% increase from 2022, as reported by IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry. Thus, the increasing focus on gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.
What Segment Categories Shape The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segment Landscape?
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
Which Trends Are Shaping Growth In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
Major companies engaged in the adeno-associated virus (AAV) vectors in the gene therapy market are dedicating efforts to advanced innovation, such as developing tailored vector diversity for assay versatility. This strategy aims to enhance target tissue specificity, improve therapeutic efficacy, and accelerate the progression of customized gene therapies for a range of indications. Tailored vector diversity for assay versatility refers to the utilization of multiple AAV serotypes or constructs to support diverse analytical tests and therapeutic applications. As an example, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, introduced new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the expanding requirements of cell and gene therapy (CGT) development. The portfolio facilitates a smoother transition from early-stage research to GMP-grade production, contributing to the standardization of processes and improved consistency in viral vector manufacturing. This launch directly addresses a critical challenge in scaling CGT programs toward achieving clinical and commercial readiness.
Who Are The Companies Operating Across The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Value Chain?
Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
Get The Full Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:
Which Region Leads The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In Terms Of Market Share?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company
Adeno Associated Viral Vectors Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
